Retatrutide raises resting heart rate. The maintenance phase has no protocol.
Retatrutide produces the largest weight loss of any GLP-1 drug in late-stage trials, and it is also the one most likely to change your resting heart rate. In the phase-3 data, the top dose raised resting heart rate by about 6.7 bpm. That number is easy to skim past on a results table. It is harder to ignore when it is your own pulse keeping you awake at 2am.
This is the side effect with no maintenance playbook. The trials measured it. The gray-market guides list it in a bullet next to nausea. Almost nobody explains why it happens, why it can surface well into a run, or what to actually watch.
The third receptor is the one that reaches your heart
Retatrutide is a triple agonist: GLP-1, GIP, and glucagon. The first two drive most of the appetite suppression. The third, glucagon, is the lever that separates retatrutide from tirzepatide and semaglutide, and it is the one with a cardiovascular footprint.
Glucagon raises energy expenditure at rest, which is part of why retatrutide produces more total weight loss (about 28% at 80 weeks in its phase-3 trial, versus roughly 22% for tirzepatide in a separate trial; no head-to-head trial has reported yet). Glucagon also raises heart rate and cardiac contractility. That is the likely mechanism behind the 6.7 bpm figure. It is not an allergic reaction or a fluke. It is the drug doing what its third receptor does.
The honest part: a sustained rise in resting heart rate is not free. Chronically elevated resting heart rate is associated with worse cardiovascular outcomes across nearly every population studied. There is no long-term retatrutide trial data yet to confirm or rule out harm from years of a higher pulse. The mechanism is worth watching closely. There is no cause for alarm at this stage.
Racing heart and broken sleep are often the same signal
Users describe two things that sound unrelated: a heart that feels like it is working too hard, and nights where sleep does not come. They tend to be the same sympathetic-like signal, and both get worse at higher doses.
There is a useful data point from a lower dose. On microdosed tirzepatide, Bryan Johnson logged resting heart rate up 3 bpm, heart-rate variability down 7, and sleep quality down about 10% after three weeks, then stopped. That was a weaker drug at a smaller dose. Retatrutide's glucagon lever pushes harder on the same axis.
Why it can surface months in, with no dose change
Retatrutide has a half-life around 6 days, so the drug keeps accumulating for roughly 3 to 4 weeks after any dose change before it settles at a steady level. That alone can lag symptoms behind a titration step.
The longer answer is confounders that build over a long cut. Months of eating less can leave blood pressure low and electrolytes depleted. Both of those can make a heart feel like it is racing and make sleep worse on their own, with no change to the drug at all. This is the same trap as the "it stopped working" complaint: the dose held steady, so people blame the drug or their body, when the thing that actually changed was underneath. If a stack or protocol turns on you after months, find what changed before you blame your body.
There is no protocol for the maintenance phase
This is the real gap. "Start low, go slow" is repeated everywhere and formalized nowhere. The minimum effective dose is undocumented art. Clinicians who run these protocols track baseline and monitoring labs (thyroid, calcitonin, and IGF-1 where relevant), but that panel is built for the ramp, not for the person who has held a steady dose for a year and whose pulse crept up.
Retatrutide is investigational. It is not FDA-approved, and there is no published, phase-specific guidance for managing sympathetic side effects during long-term maintenance. Anyone who tells you there is a settled protocol is selling something.
What to actually track
You cannot manage a heart-rate change you never baselined. If you did not record resting heart rate, heart-rate variability, and sleep before starting, you are guessing about the delta. A wearable does this well enough. The same logic applies to whether the drug is working at all: if you didn't measure a baseline, you can't tell.
Before assuming the drug is the problem, the things a clinician will usually rule out first: whether you are eating enough, whether your blood pressure is low, whether your electrolytes are down after a long cut. Those are common and fixable. A racing heart that persists after those are addressed, or a resting heart rate that keeps climbing, is a conversation to have with the clinician who signed your protocol, not a number to push through.
None of this is a reason to avoid retatrutide, and none of it is a dose recommendation. What to take, at what dose, and whether to continue belongs to you and your clinician. The point is narrower: the glucagon lever that drives retatrutide's weight-loss edge is the same lever that touches your heart, and the maintenance phase is exactly where the guidance runs out.
Whatever you decide with your clinician, the same rule about verifying claims applies. Here is how to vet a source. Or head back to the feed for the rest.